Slide 1: Investor Presentation ASX cover announcement
ImpediMed Limited 1/50 Parker Court Pinkenba, QLD, 4008 Australia E: investorrelations@impedimed.com W : impedimed.com 31 January 2025 For personal use only Companies Announcements Office Australian Securities Exchange Investor Presentation ImpediMed Limited (ASX:IPD) releases the attached presentat
Slide 2: ImpediMed Q2 FY25 Results
For personal use only Impedimed Limited Q2 FY25 Results January 2025 Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2025 ImpediMed Limited. 1
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management’s For personal use only beliefs, assumptions and expectations and on information currently available to management. All statements that address o
Slide 4: Agenda
Agenda For personal use only 1 Strategy Recap 2 Q2 Key Highlights 3 Financial Performance 4 Other Key Business Metrics 5 Q3 FY25 Outlook Proprietary, do not reproduce, distribute, or excerpt without written permission from ImpediMed. ©2025 ImpediMed Limited. 3
Slide 5: Immediate strategy
Immediate strategy Execute to breakeven with a focus of sales, marketing and clinical execution in BCRL For personal use only 12-Month Priorities Next 12 months: Execute towards break even July 2025 Next 1-2 years: Innovate and expand GOAL 1 GOAL 2 GOAL 3 GOAL 4 GOAL 5 BCRL sales World-class custome
Slide 6: Confidence in BCRL business model
Confidence in BCRL business model Building a sustainable business For personal use only Solid foundation set - ARR business model, 1,000+ devices deployed, 1 leading US healthcare customers, NCCN & NAPBC guidelines 2 Sales opportunity pipeline expanding 3 Reimbursement reaching a tipping point - a k
Slide 7: Key Q2 highlights
Key Q2 highlights Financial For personal use only • Record revenue $3.3m and cash receipts $3.4m. • Quarterly operating cash outflow ($2.5m) and cash ($17.7m) better than expected. • 7.2 quarters of operating cash, 5.2 quarters after adjusting for R&D tax credit. • 10% reduction in cash expenditure
Slide 8: Cashflow
Cashflow Summarized Cash Flow FY25 • Positive quarter financially and H1 results largely in line with expectations. For personal use only In thousands Q1 Q2 H1 AUD Actual Actual Actual • Record quarterly cash receipts of $3.4m. Receipts from customers 2,718 3,419 6,137 Research & development (88) (7
Slide 9: Revenue
Revenue Revenue Quarterly Total Revenue (excluding clinical For personal use only A$ millions revenue) A$ millions 21% p.a. • Q2 FY25 revenue up 24% vs Q1 FY25 • Long term revenue growth 21% p.a. prior to full reimbursement • 46% growth versus Q2 FY24 • Higher ROW (timing of distributor inventory re
Slide 10: ARR and TCV
ARR and TCV A$ millions For personal use only SOZO Annual Recurring Revenue1 SOZO Core Business Quarterly Total Contract Value 2 • ARR up 23% vs Q2 FY24; up 7% vs prior quarter • Difference from previous quarter largely due to a reduction of units due for renewal • ARR continues to grow as quarterly
Slide 11: Reimbursement
Reimbursement For personal use only Reimbursement remains the key to increasing sales • Not just about number of covered lives but having high % coverage in individual states • Sales traction in states with higher reimbursement • Continued growth of payor coverage in the quarter • 25 States now abov
Slide 12: Sales
Sales Global Installed Base ROW Installed Base U.S. SOZO Units Opportunity Pipeline1 For personal use only Units U.S. Installed base • 49 SOZO Units Sold +75% vs Q1FY25 • Pipeline continues to grow in response to marketing efforts • US 20 SOZO Units, ROW 29 SOZO Units • Unit opportunity +112% YOY •
Slide 13: Sales – Focus on Key Accounts
Sales – Focus on Key Accounts • Key Accounts, IDNs and NCCN Centres added or renewed Key Accounts, NCCN Institutions or IDNs For personal use only • Cleveland Clinic, Sutter Health, Memorial Sloane Kettering, Baylor Scott added or renewed in Q2 FY25 & White, Northwell Health, Mass General Brigham, V
Slide 14: Patient Testing
Patient Testing Patient Tests (000s) SOZO® measures & tracks For personal use only • 70,000 Patient Tests in Q2 FY25 critical patient data • Down 1% versus Q1 FY25 overall • U.S. region up 2% Q/Q • L-Dex ® Lymphoedema index • Reduction in testing in UK and Asia after above • HF-DexTM Heart Failure i
Slide 15: Q2 FY25 vs Outlook
Q2 FY25 vs Outlook For personal use only ❑ Accelerate sales strategy ❑ Continued focus on Lymphoedema awareness activities to generate leads ❑ Optimise contract renewal outcomes ❑ Drive further improvement in sales and other key business metrics ❑ Further expansion of private payor coverage ❑ Contin
Slide 16: Outlook for Q3 FY25
Outlook for Q3 FY25 For personal use only ❑ Continued to initiate Lymphoedema awareness activities to generate leads ❑ Measured investment to accelerate sales strategy ❑ Continued focus on private payor coverage ❑ Drive improvement in sales metrics ❑ Optimise contract renewal outcomes ❑ Continued fo
Slide 17: The Value Proposition
The Value Proposition Multiple Regulatory Clearances For personal use only Lymphoedema Heart Failure Reimbursement Renal Failure 75% of US Body Comp Successful Insured Lives covered Global RCT Lymphoedema Critical mass prevention coverage in 25 US States Guideline and Initial TAM Standard $600M Incl
Slide 18: For personal use only
impedimed’ Ajuo asn jeuosiad 4104 a7